PARTICIPATION IN CALGB

UMCC在其科学和技术方面一直在持续增长 与CALGB的临床关系。UMCC教职员工参与 行政、科学、委员会和规划活动 在CALGB内。UMCC教职员工的设计、指挥和主席 许多团体研究并输入了大量的患者(PTS)。 到CALGB协议上。UMCC教职员工主持两大 小组内的委员会，是负责任的调查人员 进行了大量的研究。为继续和扩大提供资金 这些活动将使各国能够进一步大力参与 UMCC在全组研究中。例如，UMCC内部第一阶段 (每年2至4项)研究经常进入集团范围的第二阶段 学习。UMCC还进行试点研究，形成了 全集团研究的概念基础。UMCC是单人 PTS最大的应计机构。患有急性白血病和 基础科学实验室研究这种疾病是有价值的 资源分配给组。这些专业实验室包括 作为资源的细胞遗传学和药理学 未来CALGB的合作努力和创新基础 互动式实验室/临床研究。UMCC及其智能交通系统 合作机构(退伍军人医疗中心-巴尔的摩； 特拉华州医疗中心)和大巴尔的摩 医疗中心)建议在250以上进一步增加应计项目 每年进入CALGB研究的方案条目。这是一个应计项目 集团中最大的一家。参加CALGB研究将 允许UMCC及其合作医生获得更好的治疗 PTS的选项。疾病正在由该组织研究。UMCC 当前输入PTS。关于急性白血病、小细胞肺的试验 癌症、乳腺癌和淋巴瘤。辅助研究包括 评价阿糖胞苷的细胞药理和敏感性 作为白血病细胞的细胞遗传学利用标准和 甲氨蝶呤同步拆分技术。目前有许多 CALGB集团范围内的积极研究部分源自Pilot 来自UMCC的数据包括对急性白血病、乳房 癌症、小细胞肺癌和UMCC实验室将 为这些荷尔蒙研究提供药理学支持。资金支持 基础科学实验室，如研究小细胞肺的实验室 癌症生物学和生长调节作为群体资源 互动式实验室临床试验。UMCC试点研究 乳腺癌的激素治疗开辟了一个新领域 为乳腺癌患者提供的治疗方案。UMCC也 参与选定的CALGB第二阶段研究以及 罕见的肿瘤通过以下途径进入组间研究 CALGB。这笔拨款将允许UMCC继续进入PTS。 对CALGB的研究并继续提供强有力的科学 投入到群体科学和群体管理活动中。 这笔赠款还将允许功勋飞行员继续留任 协议，并将允许UMCC监控和收集 将对UMCC和CALGB产生互惠互利。

The UMCC has had ever continuing growth in its scientific and clinical relationships with CALGB. UMCC faculty participate in administrative, scientific, committee and planning activities within the CALGB. The UMCC faculty design, conduct and chair many groups studies and enter large numbers of patients (pts.) onto CALGB protocols. UMCC faculty chair two major committees within the group and are the responsible investigators for a large number of studies. Funding to continue and expand these activities will allow for further strong participation of UMCC in groupwide studies. For example, UMCC inhouse phase I (2 to 4 per year) studies frequently evolve into groupwide phase II studies. UMCC also conducts pilot studies which have formed the conceptual bases for groupwide studies. UMCC is the single largest accruing institution for pts. with acute leukemia and the basic science laboratories studying this disease is a valuable resource to the group. These specialized laboratories include cytogenetics and pharmacology which serve as a resource for collaborative efforts and innovative bases for future CALGB interactive laboratory/clinical studies. UMCC and its collaborating institutions (VA Medical Center - Baltimore; Medical Center of Delaware CCOP), and Greater Baltimore Medical Center) propose to further increment accrual beyond 250 protocol entries per year onto CALGB studies. This accrual is one of the largest in the group. Participation in CALGB studies will allow UMCC and its collaborating physicians greater treatment options for pts. with diseases under study by the group. UMCC currently enters pts. onto trials in acute leukemia, small cell lung cancer, breast cancer, and lymphoma. Ancillary studies are evaluating cellular pharmacology and sensitivity of Ara-C as well as the cytogenetics of leukemia cells utilizing standard and methotrexate synchronized resolution techniques. Many currently active CALGB groupwide studies are derived in part from pilot data from the UMCC including studies in acute leukemia, breast cancer, and small cell lung cancer and UMCC laboratories will provide pharmacology support for these hormone studies. Funded basic science laboratories such as those studying small cell lung cancer biology and growth modulation act as group resources for interactive laboratory clinical trials. UMCC pilot studies in hormonal treatment of breast cancer have opened up a new area of treatment for the group in breast cancer. UMCC also participates in selected CALGB phase II studies as well as uncommon tumors entered onto intergroup studies through CALGB. This grant will allow UMCC to continue to enter pts. onto CALGB studies and continue to provide a strong scientific input into the group science and group administrative activities. This grant will also allow for the continuation of meritorious pilot protocols and will allow UMCC to monitor and collect data which will produce mutual benefit to the UMCC and the CALGB.